20th Aug 2008 12:52
|
For Immediate Release
|
20 August 2008
|
Meldex International Plc
|
TR - 1: |
NOTIFICATION OF MAJOR INTERESTS IN SHARES |
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Meldex International Plc
2. Reason for the notification (please tick the appropriate box or boxes):
|
An acquisition or disposal of voting rights |
|
|
An event changing the breakdown of voting rights |
3. Full name of person(s) subject to the notification obligation:
Barclays PLC
4. Full name of shareholder(s) (if different from 3.)
n/a
5. Date of the transaction and date on which the threshold is crossed or reached:
August 18, 2008
6. Date on which issuer notified:
August 19, 2008
7. Threshold(s) that is/are crossed or reached:
8% to 7%
8. Notified details:
|
A: Voting rights attached to shares |
|
Class/type of shares if possible using the ISIN CODE |
Situation previous to the Triggering transaction |
Resulting situation after the triggering transaction |
|||||
|
Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights |
|||
|
Direct |
Indirect |
Direct |
Indirect |
||||
|
GB0032681628 |
17,254,723 |
17,254,723 |
17,255,023 |
0 |
17,225,023 |
0.00 |
7.66 |
|
Total (A+B) |
|
Number of voting rights |
% of voting rights |
|
17,225,023 |
7.66 |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable
Barclays Stockbrokers Ltd
Proxy Voting:
10. Name of the proxy holder:
n/a
11. Number of voting rights proxy holder will cease to hold:
n/a
12. Date on which proxy holder will cease to hold voting rights:
n/a
For further information:
|
Meldex International Plc |
+ 44 (0) 20 7098 9880 |
|
Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO |
|
|
|
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Rebecca Skye Dietrich Mark Court |
|
About Meldex International Plc
Meldex International plc is an innovative specialty pharmaceutical and OTC product Company. Listed on London's AIM in May 2003, the Company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007 for a consideration of up to €35m, Melbrosin's focus is on consumer over the counter health care products based on substances of natural and plant origin, which are developed into consumer orientated brands then scaled, produced and distributed by Melbrosin. The Melbrosin complements the prescription pharmaceutical sales and marketing business created and expanded in 2006.
The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners using its proprietary XGEL™ polymer technology. For further information please go to www.meldexinternational.com
Related Shares:
Barclays